EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase I)

Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer

Kathryn C Arbour, Salman Punekar, Jia Luo iD, Melissa Johnson, Alexander Spira, Benjamin Herzberg, Alexander Starodub, David Sommerhalder, Joel Randolph Hecht, Ignacio Garrido-Laguna, Minal Barve, Sai-Hong Ignatius Ou und 9 weitere

New England Journal of Medicine · 03.09.2026 · 395 (9) · 882-893

DOI: 10.1056/nejmoa2504059 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift New England Journal of Medicine, erschienen am 03.09.2026. Verfasst von Kathryn C Arbour und 20 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Piperazines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Revolution Medicines.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsPiperazinesProto-Oncogene Proteins p21(ras)AdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedDose-Response Relationship, DrugMutationDrug Administration ScheduleAdministration, OralResponse Evaluation Criteria in Solid Tumors

Substanzen

Antineoplastic AgentsdaraxonrasibPiperazinesProto-Oncogene Proteins p21(ras)

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, New York.
  • Weill Cornell Medical College, New York.
  • NYU Langone Health, New York.
  • Dana-Farber Cancer Institute, Boston.
  • Brigham and Women's Hospital, Boston.
  • Harvard Medical School, Boston.

ORCID-Profile: Jia Luo

Förderung

  • Revolution Medicines

Zitieren

APA

Arbour, K. C., Punekar, S., Luo, J., Johnson, M., Spira, A., Herzberg, B., Starodub, A., Sommerhalder, D., Hecht, J. R., Garrido-Laguna, I., Barve, M., Ou, S. I., Kar, S., Bao, L., Tao, L., Vora, R., Hegde, A., Saltos, A., Azad, N. S., …, & RMC-6236-001 Investigators (2026). Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine, 395(9), 882-893. https://doi.org/10.1056/nejmoa2504059

Vancouver

Arbour KC, Punekar S, Luo J, Johnson M, Spira A, Herzberg B, et al. Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2026;395(9):882-893. doi:10.1056/nejmoa2504059

BibTeX
@article{Arbour2026,
  author = {Arbour, Kathryn C and Punekar, Salman and Luo, Jia and Johnson, Melissa and Spira, Alexander and Herzberg, Benjamin and Starodub, Alexander and Sommerhalder, David and Hecht, Joel Randolph and Garrido-Laguna, Ignacio and Barve, Minal and Ou, Sai-Hong Ignatius and Kar, Sumit and Bao, Lei and Tao, Lin and Vora, Rashmi and Hegde, Aparna and Saltos, Andreas and Azad, Nilofer S and Hong, David S and RMC-6236-001 Investigators, RMC-6236-001 Investigators},
  title = {Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {9},
  pages = {882--893},
  doi = {10.1056/nejmoa2504059}
}
Kostenlos starten →